Inspire Medical Systems, Inc.INSPEarnings & Financial Report
Inspire Medical Systems, Inc. is a medical technology firm that develops, manufactures and commercializes implantable neurostimulation solutions for obstructive sleep apnea. Its core product serves patients intolerant to CPAP therapy, with main markets across North America, Europe, and select Asia-Pacific regions, operating in sleep medicine and otolaryngology segments.
Revenue
$239.7M
Gross Profit
$203.7M
Operating Profit
$31.9M
Net Profit
$35.2M
Gross Margin
85.0%
Operating Margin
13.3%
Net Margin
14.7%
YoY Growth
24.5%
EPS
$1.17
Inspire Medical Systems, Inc. Q4 FY2024 Financial Summary
Inspire Medical Systems, Inc. reported revenue of $239.7M (up 24.5% YoY) for Q4 FY2024, with a net profit of $35.2M (up 138.6% YoY) (14.7% margin). Cost of goods sold was $36.0M, operating expenses totaled $171.8M.
Key Financial Metrics
| Total Revenue | $239.7M |
|---|---|
| Net Profit | $35.2M |
| Gross Margin | 85.0% |
| Operating Margin | 13.3% |
| Report Period | Q4 FY2024 |
Inspire Medical Systems, Inc. Annual Revenue by Year
Inspire Medical Systems, Inc. annual revenue history includes year-by-year totals (for example, 2025 revenue was $912.0M).
| Year | Annual Revenue |
|---|---|
| 2025 | $912.0M |
| 2024 | $802.8M |
| 2023 | $624.8M |
| 2022 | $407.9M |
Inspire Medical Systems, Inc. Quarterly Revenue & Net Profit History
Inspire Medical Systems, Inc. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q1 FY2026 | $204.6M | +1.6% | N/A | N/A |
| Q4 FY2025 | $269.1M | +12.2% | $136.1M | 50.6% |
| Q3 FY2025 | $224.5M | +10.5% | $9.9M | 4.4% |
| Q2 FY2025 | $217.1M | +10.8% | $-3.6M | -1.7% |
| Q1 FY2025 | $201.3M | +22.7% | $3.0M | 1.5% |
| Q4 FY2024 | $239.7M | +24.5% | $35.2M | 14.7% |
| Q3 FY2024 | $203.2M | +32.5% | $18.5M | 9.1% |
| Q2 FY2024 | $195.9M | +29.6% | $9.8M | 5.0% |
Income Statement
| Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $195.9M | $203.2M | $239.7M | $201.3M | $217.1M | $224.5M | $269.1M | $204.6M |
| YoY Growth | 29.6% | 32.5% | 24.5% | 22.7% | 10.8% | 10.5% | 12.2% | 1.6% |
Balance Sheet
| Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $728.4M | $796.2M | $808.4M | $730.8M | $802.2M | $807.7M | $907.3M | $911.4M |
| Liabilities | $90.3M | $99.6M | $118.7M | $95.1M | $124.4M | $141.3M | $126.2M | $119.0M |
| Equity | $638.1M | $696.6M | $689.7M | $635.7M | $677.8M | $666.5M | $781.2M | $792.3M |
Cash Flow
| Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|
| Operating CF | $-78000 | $52.3M | $69.2M | $-6.7M | $2.7M | $68.5M | $52.5M |